Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Dose Escalation Trial of Radiodynamic Therapy (RDT) With 5-Aminolevulinic Acid in Patients With First Recurrence of Glioblastoma

NCT05590689 is registered in ClinicalTrials.gov with Universität Münster as lead sponsor.

NCT NCT05590689
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05590689 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Dose Escalation Trial of Radiodynamic Therapy (RDT) With 5-Aminolevulinic Acid in Patients With First Recurrence of Glioblastoma
Lead sponsor
Universität Münster
Phase
Phase 1/2
Overall status
Recruiting
Start date
November 9, 2022
Completion date
January 31, 2028
Enrollment
34 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma